Sino Biopharmaceutical Limited
SBMFF
$0.9891
$0.03914.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 418.45M | 418.45M | 418.45M | 299.95M | 181.81M |
| Total Depreciation and Amortization | 70.76M | 70.76M | 70.76M | 80.54M | 91.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -62.26M | -62.26M | -62.26M | 24.51M | 112.89M |
| Change in Net Operating Assets | -- | -- | -- | -- | -- |
| Cash from Operations | 426.96M | 426.96M | 426.96M | 405.00M | 385.80M |
| Capital Expenditure | -56.52M | -56.52M | -56.52M | -82.17M | -108.89M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 32.70K | 66.20K |
| Divestitures | 195.51M | 195.51M | 195.51M | 98.18M | -- |
| Other Investing Activities | -422.05M | -422.05M | -422.05M | -448.92M | -479.70M |
| Cash from Investing | -283.06M | -283.06M | -283.06M | -432.89M | -588.53M |
| Total Debt Issued | 6.71B | 6.71B | 6.71B | 8.82B | 10.93B |
| Total Debt Repaid | -9.40B | -9.40B | -9.40B | -11.63B | -13.87B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -361.55M | -361.55M | -361.55M | -298.63M | -235.70M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.05B | -1.05B | -1.05B | -958.76M | -863.33M |
| Cash from Financing | -568.56M | -568.56M | -568.56M | -573.93M | -583.82M |
| Foreign Exchange rate Adjustments | 3.64M | 3.64M | 3.64M | 7.88M | 12.25M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -421.01M | -421.01M | -421.01M | -593.94M | -774.29M |